CO61

ISATUXIMAB IN MULTIPLE MYELOMA: SAFETY AND EFFECTIVENESS

Moñino Domínguez L, Carrión Madroñal IM, Marcos Rodríguez JA, Valera Rubio M.
Pharmacy Department. University Hospital Virgen Macarena. Spain

OBJECTIVE

To analyse effectiveness and safety of isatuximab in patients with Multiple Myeloma(MM)

METHODS

Retrospective observational study was conducted. We included patients treated with isatuximab in combination with carfilzomib-dexamethasone or pomalidomide-dexamethasone from June/2022-March/2023. Variables collected: sex, age, type of MM, staging according to the International Staging System(R-ISS), high-risk cytogenetic alterations(HRCA), disease follow-up time, receipt of autologous Hematopoietic Cell Transplantation(AHCT), drug in combination with isatuximab, duration and number of cycles, previous chemotherapy regimens, overall response rate(ORR) and progression-free survival(PFS) calculated by Kaplan-Meier method, and adverse events(AEs) reported.

RESULTS

▪7 patients (71,4% female) were included. Median age was 62 years (IQR:55-70)

▪**Type of MM**: 57.1% IgG-kappa, 14.3% IgG-lambda, 14.3% IgA-kappa and 14.3% light-chain-lambda

▪**R-ISS:3** 42.9%; **R-ISS:2** 28.6% (28.5% no data recorded)

▪**HRCAs** → 1q gain: 57.1%, IgH-FGFR3-t(4;14) rearrangement: 42.9% and p53 (17p13):14.3%

▪At the start of treatment, patients had been diagnosed for a median of 22 months(IQR:14-33)

▪14.3% had received **AHCT**

Most frequent AEs

Our study	% Patients
Infusional reactions	28,6%
Nausea-vomiting	28,6% (G3:0%)
upper respiratory tract infections	28,6% (G3:0%)

Isatuximab in combination with:



Median PFS: NOT REACHED
2 patients progressed
At 3 months 64.3% had **not progressed**.

ORR was partial in 28.6% of patients

▪Mean number of isatuximab **cycles received**= 4.3(±2)

▪Patients had a mean of 2.8(±1,19) previous **chemotherapy lines**(100% on lines including bortezomib and lenalidomide).

42,8% patients

- 28,6% progression
- 28,6% to start AHCT

CONCLUSION

Median PFS was not reached in our study, which prevents us from comparing the results with the pivotal trial due to the immature data. Further studies with a larger sample size and longer follow-up period are needed to confirm these real-life results.
It shows a good safety and tolerability profile in our patients.

modominguezlaura@gmail.com